

## Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review

\*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

\*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

### Abstract

Body Mass Index (BMI) is a crucial determinant of nutritional status and overall health, particularly impactful in individuals facing concurrent diagnoses of leukemia and HIV/AIDS. This review examines the intricate relationship between BMI variations and quality of life (QoL) in leukemia patients living with HIV, aiming to elucidate the multifaceted mechanisms underlying their interconnectedness. Through an extensive synthesis of existing literature, this review provides insights into how BMI fluctuations influence not only metabolic health and immune function but also psychosocial well-being, ultimately shaping QoL outcomes in this vulnerable patient population. Leukemia and HIV/AIDS represent significant health challenges individually, with their coexistence posing unique clinical complexities. BMI emerges as a tangible indicator of nutritional status, reflecting metabolic imbalances and nutritional deficiencies prevalent in leukemia patients living with HIV. Maintaining optimal BMI levels assumes paramount importance in supporting immune function, enhancing treatment responses, and mitigating treatment-related toxicities, all of which are integral to improving QoL outcomes. BMI variations exert profound effects on treatment responses and clinical outcomes in leukemia patients living with HIV. Low BMI is associated with heightened treatment-related morbidity and mortality, as well as diminished treatment efficacy. Conversely, elevated BMI may confer resistance to certain therapies and increase the risk of metabolic complications, further impacting QoL and treatment outcomes. Understanding these dynamics is essential for tailoring therapeutic strategies to optimize QoL and enhance overall well-being in this vulnerable patient population.

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

**Keywords:** *Body Mass Index, Quality of Life, Leukemia, HIV/AIDS, Nutritional Status, Treatment Response, Immune Function*

## Introduction

The coexistence of leukemia and HIV/AIDS presents a formidable challenge to healthcare providers, requiring a comprehensive understanding of the intricate interplay between disease processes, treatment modalities, and patient outcomes. Body Mass Index (BMI), a widely used measure of nutritional status, emerges as a critical determinant of health in individuals grappling with these dual burdens. BMI serves as a tangible indicator of metabolic health, immune function, and overall well-being, with deviations from the norm signaling underlying vulnerabilities that can impact disease trajectories and treatment responses.<sup>1-5</sup> Leukemia, a hematological malignancy characterized by abnormal proliferation of blood cells, and HIV/AIDS, a viral infection that compromises immune function, intersect to create a complex clinical scenario marked by heightened susceptibility to malnutrition, immune dysfunction, and treatment-related complications. BMI assumes particular significance in this context, as it reflects the balance between energy intake and expenditure, and provides valuable insights into the nutritional status of patients facing these intertwined diseases.<sup>6-10</sup> The impact of BMI variations extends beyond mere nutritional considerations to encompass broader implications for treatment responses, disease progression, and quality of life (QoL) outcomes in leukemia patients living with HIV. Low BMI levels are often associated with malnutrition, immune compromise, and increased treatment-related toxicities, leading to poorer treatment responses and survival outcomes. Conversely, elevated BMI levels may signify chronic inflammation, metabolic dysfunction, and treatment resistance, further complicating the management of these patients and diminishing treatment efficacy.<sup>11-15</sup>

## BMI and Nutritional Status

Body Mass Index (BMI) serves as a pivotal metric for assessing the nutritional status of individuals, providing valuable insights into their overall health and well-being. Defined as the ratio of an individual's weight to the square of their height, BMI offers a simple yet effective means of categorizing individuals into different weight status categories, such as underweight, normal weight, overweight, and obesity. In the context of leukemia patients living with HIV, BMI assumes particular significance due to the profound impact of these diseases on metabolic processes, nutrient utilization, and immune function.<sup>16-20</sup> Leukemia, a malignancy characterized by abnormal proliferation of blood cells, and HIV/AIDS, a viral infection that compromises immune function, collectively contribute to a complex clinical landscape marked by heightened vulnerability to malnutrition and its associated complications. The interplay between these diseases can disrupt metabolic homeostasis, leading to alterations in energy balance, nutrient metabolism, and body composition. As a result, maintaining optimal BMI levels becomes crucial for supporting immune

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

function, enhancing treatment responses, and improving overall outcomes in leukemia patients living with HIV.<sup>21-25</sup>

Malnutrition, a prevalent complication in this population, can significantly impact treatment tolerance, response rates, and survival outcomes. Low BMI levels often reflect underlying nutritional deficiencies, including protein-energy malnutrition, micronutrient deficiencies, and cachexia, all of which can compromise immune function and exacerbate treatment-related toxicities. Additionally, malnutrition may impair the body's ability to withstand the cytotoxic effects of chemotherapy and antiretroviral therapy, further complicating the management of these patients and diminishing treatment efficacy.<sup>26-30</sup> Addressing the nutritional needs of leukemia patients living with HIV requires a comprehensive approach that encompasses nutritional assessment, dietary counseling, and targeted interventions to optimize BMI status. Nutritional assessment, including evaluation of BMI, dietary intake, and biochemical markers, plays a crucial role in identifying patients at risk of malnutrition and guiding appropriate interventions. Tailored nutritional supplementation, including oral nutritional supplements, enteral feeding, and parenteral nutrition, may be necessary to meet the increased energy and protein requirements of these patients and mitigate the effects of malnutrition on treatment outcomes.<sup>31-35</sup> Furthermore, nutritional counseling and support are essential components of care for leukemia patients living with HIV, providing education on healthy eating habits, dietary modifications, and strategies to manage treatment-related side effects. Multidisciplinary collaboration among oncologists, infectious disease specialists, dietitians, and other healthcare providers is essential to ensure coordinated and individualized care that addresses the diverse nutritional needs of these patients. By optimizing BMI status and addressing underlying nutritional deficiencies, healthcare providers can enhance treatment tolerance, improve treatment responses, and ultimately, improve the quality of life for leukemia patients living with HIV.<sup>35-40</sup>

### **Impact on Treatment Response**

The impact of Body Mass Index (BMI) on treatment response in leukemia patients living with HIV/AIDS is multifaceted, encompassing physiological, pharmacokinetic, and immunological factors that influence therapeutic outcomes. BMI serves as a surrogate marker of metabolic health and nutritional status, with deviations from the norm affecting the efficacy and tolerability of chemotherapy and antiretroviral therapy, thereby shaping treatment responses and clinical outcomes.<sup>41-45</sup> Low BMI levels are commonly associated with diminished treatment tolerance and increased susceptibility to treatment-related toxicities in leukemia patients living with HIV/AIDS. Malnutrition, often indicated by low BMI, compromises the body's ability to withstand the cytotoxic effects of chemotherapy and antiretroviral medications, leading to higher rates of treatment interruptions, dose reductions, and treatment-related complications. Consequently, patients with low BMI may experience suboptimal treatment responses and poorer survival outcomes compared to those with normal or elevated BMI.<sup>46-50</sup>

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

Moreover, BMI variations can impact the pharmacokinetics of chemotherapy agents and antiretroviral medications, influencing drug distribution, metabolism, and elimination. In patients with low BMI, altered drug metabolism and distribution may result in subtherapeutic drug levels, reducing the effectiveness of treatment and increasing the risk of disease progression and relapse. Conversely, in patients with elevated BMI, altered drug metabolism and distribution may lead to increased drug exposure and toxicity, necessitating dose adjustments and careful monitoring to minimize adverse effects.<sup>51-55</sup> The relationship between BMI and treatment response is further complicated by the presence of comorbidities commonly observed in leukemia patients living with HIV/AIDS, such as metabolic syndrome, insulin resistance, and dyslipidemia. These comorbidities can affect drug metabolism and distribution, exacerbating treatment-related toxicities and compromising treatment efficacy. Additionally, the immune dysregulation associated with HIV/AIDS can impact the body's ability to mount an effective antitumor response, further influencing treatment outcomes in this patient population.<sup>56-60</sup> Optimizing treatment responses in leukemia patients living with HIV/AIDS requires a personalized approach that takes into account BMI status, nutritional status, comorbidities, and immune function. Tailored treatment regimens, including dose adjustments based on BMI and pharmacokinetic parameters, may be necessary to achieve optimal therapeutic outcomes while minimizing treatment-related toxicities. Furthermore, supportive care measures, including nutritional supplementation, management of comorbidities, and psychosocial support, play a crucial role in enhancing treatment tolerance and improving treatment responses in this vulnerable population.<sup>61-65</sup>

### **Immunological Implications**

The immunological implications of Body Mass Index (BMI) variations in leukemia patients living with HIV/AIDS are profound, reflecting the intricate interplay between metabolic health, nutritional status, and immune function. BMI serves as a surrogate marker of immune competence, with deviations from the norm indicative of underlying immunological dysfunction. In this vulnerable population, aberrant BMI trajectories are associated with dysregulated cytokine profiles, disrupted lymphocyte subsets, and compromised immune surveillance, all of which have significant implications for disease progression, treatment response, and overall prognosis.<sup>66-70</sup> Low BMI levels are often indicative of malnutrition and immune compromise in leukemia patients living with HIV/AIDS. Malnutrition not only impairs the production and function of immune cells, including T cells, B cells, and natural killer cells, but also compromises the body's ability to mount an effective immune response against leukemia cells and opportunistic infections. Consequently, patients with low BMI may experience more frequent and severe infections, higher rates of treatment-related complications, and poorer long-term outcomes compared to those with normal or elevated BMI.<sup>71-75</sup>

Conversely, elevated BMI levels are associated with chronic inflammation and immune dysregulation, which can contribute to disease progression and treatment resistance in leukemia patients living with HIV/AIDS. Adipose tissue serves as a reservoir for pro-inflammatory

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

cytokines, such as tumor necrosis factor-alpha (TNF- $\alpha$ ) and interleukin-6 (IL-6), which can promote leukemia cell proliferation, survival, and resistance to chemotherapy. Additionally, adipose tissue dysfunction and insulin resistance, commonly observed in patients with elevated BMI, can further exacerbate immune dysfunction and impair treatment responses.<sup>76-80</sup> The immunological implications of BMI variations extend beyond the direct effects on immune function to impact the efficacy of immunotherapy and other immune-based treatments in leukemia patients living with HIV/AIDS. Immunotherapeutic approaches, such as checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and therapeutic vaccines, rely on intact immune function for their effectiveness. Therefore, BMI-related alterations in immune function and inflammatory status may influence the response to immunotherapy and contribute to variability in treatment outcomes among patients with different BMI levels.<sup>81-85</sup>

### **Psychosocial Considerations**

Psychosocial considerations play a critical role in the well-being and quality of life of leukemia patients living with HIV/AIDS, and Body Mass Index (BMI) variations can significantly impact these factors. The psychosocial implications of BMI extend beyond physical health to encompass body image concerns, stigma, treatment adherence, and overall psychological well-being.<sup>86-90</sup> Body image concerns are common among leukemia patients living with HIV/AIDS, particularly those who experience BMI fluctuations due to treatment side effects or metabolic changes. Changes in weight and body composition can impact self-esteem, body image, and overall satisfaction with physical appearance, leading to feelings of distress, embarrassment, or social isolation. Healthcare providers play a crucial role in addressing these concerns by providing empathetic support, counseling, and resources to help patients cope with changes in their body image.<sup>91-95</sup> Stigma surrounding HIV/AIDS and leukemia can also exacerbate psychosocial distress in affected individuals, particularly those who experience weight loss or changes in BMI. Stigma may manifest as fear of rejection, discrimination, or social isolation, further compounding the psychological burden of living with chronic illnesses. Healthcare providers must be attuned to these psychosocial challenges and provide a supportive and nonjudgmental environment where patients feel safe to express their concerns and seek assistance.<sup>91-105</sup> Treatment adherence is another critical psychosocial consideration in leukemia patients living with HIV/AIDS, and BMI variations can impact medication adherence and treatment outcomes. Patients with low BMI may experience challenges with medication tolerance or adherence due to treatment-related toxicities or side effects, while those with elevated BMI may face barriers related to medication access, affordability, or concerns about weight gain. Addressing these barriers requires a collaborative approach involving healthcare providers, patients, and support networks to develop strategies to optimize treatment adherence and minimize treatment interruptions.<sup>106-118</sup>

### **Conclusion**

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

Body Mass Index (BMI) variations have profound implications for the quality of life and overall well-being of leukemia patients living with HIV/AIDS. Throughout this review, we have explored the multifaceted impact of BMI on various aspects of patient care, including nutritional status, treatment response, immune function, and psychosocial considerations. It is evident that BMI serves as more than just a measure of body weight; rather, it serves as a critical indicator of metabolic health, nutritional status, and immune competence, with deviations from the norm influencing disease trajectories and treatment outcomes. Optimizing BMI status is essential for supporting immune function, enhancing treatment responses, and improving overall survival outcomes in leukemia patients living with HIV/AIDS. Malnutrition, often indicated by low BMI, compromises immune function and treatment tolerance, leading to increased susceptibility to infections and poorer treatment outcomes. Conversely, elevated BMI levels may be associated with chronic inflammation and metabolic dysfunction, further complicating the management of these patients and diminishing treatment efficacy.

## References

1. Zhao Y, Forst CV, Sayegh CE, Wang IM, Yang X, Zhang B. Molecular and genetic inflammation networks in major human diseases. *Molecular BioSystems*. 2016;12(8):2318-2341.
2. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. *Annu. Rev. Immunol.* 2004; 22:625-655.
3. Tulchinsky TH, Varavikova EA. Measuring, monitoring, and evaluating the health of a population. *The New Public Health*. 2014:91.
4. Obeagu EI, Omar DM, Omar U. Leukaemia burden in Africa. *Int. J. Curr. Res. Biol. Med.* 2023; 1:17-22.
5. Obeagu EI, Nakyeyune S, Muhimbura E, Owunna TA, Uwakwe OS. Evaluation of haematological manifestations in patients with acute myeloid leukaemia in a tertiary hospital in uganda. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):58-63.
6. Obeagu EI, Obeagu GU. Studies on platelets diagnostic indexes in patients with acute myeloid leukaemia in Uganda. *Int. J. Curr. Res. Med. Sci.* 2023;9(1):24-7.
7. Obeagu EI, Gnanavel K. An Insight on Acute Myeloid Leukemia: Pediatric Perspective. *Journal home page: <http://www.journalijiar.com>*. 2022;10(03).
8. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
9. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54



10. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
11. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
12. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
13. Obeagu EI, Obeagu GU. The Impact of Body Mass Index (BMI) on Immune Function in Leukemia Patients Living with HIV: A Review. Elite Journal of Immunology. 2024;2(4):73-92.
14. Obeagu EI, Obeagu GU. The Nexus Between Obesity and Leukemia Progression in HIV-Positive Individuals: A Review. Elite Journal of Haematology, 2024; 2 (4):180-98.
15. Jolles S, Giralt S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, Reiser M, Ria R, Vinh DC, Wingard JR. Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel. Blood Reviews. 2023; 58:101020.
16. Simon TG, Butt AA. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World Journal of Gastroenterology: WJG. 2015;21(27):8293.
17. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets and Some Inflammation Markers Of Patients With Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Oct 1;2(3):78-84.
18. Obeagu EI, Babar Q. Acute Myeloid Leukaemia (AML): The Good, the Bad, and the Ugly. Int. J. Curr. Res. Med. Sci. 2021;7(7):29-41.
19. Anyiam AF, Musa Muhibi MA, Iyare G, Omosigho PO, Olaniyan MF, Arinze-Anyiam OC, Oluwafemi E, Obeagu EI. Effects of different Extracts of Phyllanthus amarus on selected haematological and haemostatic parameters of Leukemic Wistar Rats. Elite Journal of Medica Science. 2024;2(1):23-43.
20. Obeagu EI, Udemezue EC, Akalonu BO, Babar Q. Plasma Cell Leukaemia (PCL): A Review. Asian Hematology Research Journal. 2021;5(3):36-8.
21. Obeagu EI, Obeagu GU, Amilo GI. Evaluation of Haematological Changes Associated to Non-Hodgkin Lymphoma in Subjects in Enugu State, South East, Nigeria. Arch Blood Transfus Disord. 2017; 1:1-4.
22. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

23. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
24. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
25. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
26. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.5923/BJO.2016050464).
27. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, De Wit TD, Eichinger S, Fibbe W, Green T, De Haas F. The European hematology association roadmap for European hematology research: a consensus document. *haematologica*. 2016;101(2):115.
28. Ifeanyi OE. Acute Leukaemia: A Sudden Killer to Human Beings. *EC Emergency Medicine and Critical Care*. 2020;4(6):154-167.
29. Abunimye DA, Okafor IM, Okorowo H, Obeagu EI. The role of GATA family transcriptional factors in haematological malignancies: A review. *Medicine*. 2024;103(12):e37487.
30. Obeagu EI, Okoroiwu IL, Daniel-Igwe G, Nnah IS. Hematology in the Senescence. *European Journal of Biomedical and Pharmaceutical Sciences*. 2015;2(3):97-107.
31. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.  
[https://www.academia.edu/download/38320140/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
32. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
33. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.  
[links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.5923/IJPBS.2017120407)

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54



34. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
35. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30.  
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.epjournals.com/journals/EJH/links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).
36. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144.  
[https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJC\\_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
37. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4.  
[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.epjournals.com/journals/EJH/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
38. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
39. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports*. 2023;6(8):e1450.
40. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139.  
[links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://www.epjournals.com/journals/EJH/links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf).
41. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):128-134.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
42. Gutin I. In BMI we trust: reframing the body mass index as a measure of health. *Social Theory & Health*. 2018; 16:256-271.

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

43. Wynne C, Comiskey C, Hollywood E, Quirke MB, O'Sullivan K, McGilloway S. The relationship between body mass index and health-related quality of life in urban disadvantaged children. *Quality of Life Research*. 2014; 23:1895-1905.
44. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2022;29-34.
45. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeke M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18.
46. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.2196/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf).
47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf).
49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 [https://www.academia.edu/download/54317126/Haematological\\_indices\\_of\\_malaria\\_patients\\_coinfected\\_with\\_HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
50. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31.
51. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-183.DOI: DOI: 10.32474/JCCM.2020.02.000137 [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-](https://doi.org/10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-)

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

[Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](#)

52. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.
53. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023;6(1):203-211.  
<http://research.sdpublishers.net/id/eprint/2819/>.
54. Parisi E, Glick M. Immune suppression and considerations for dental care. *Dental Clinics*. 2003;47(4):709-731.
55. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
56. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
57. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
58. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.  
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.wjps.in/links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
59. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.
60. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcreps.in/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
61. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):6-13.DOI:

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

- 10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
62. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508acebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/links/5711c47508acebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
  63. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910. [https://www.academia.edu/download/38320134/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
  64. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
  65. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
  66. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
  67. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharma Research.* 2014; 391:186-189.
  68. Joseph J, Sandel G, Kulkarni R, Alatrash R, Herrera BB, Jain P. Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS. *Pathogens.* 2023;13(1):14.
  69. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
  70. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
  71. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

72. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
73. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
74. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).
75. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
76. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
77. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
78. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
79. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore).* 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
80. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore).* 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
81. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
82. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
83. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
84. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health.* 2024;2(1):8-22.

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54



85. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
86. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024;103(9): e37354.
87. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
88. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
89. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
90. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
91. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>;12(01)*.
92. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
93. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. *The international journal of tuberculosis and lung disease*. 2004;8(3):286-298.
94. Knight ET, Liu J, Seymour GJ, Faggion Jr CM, Cullinan MP. Risk factors that may modify the innate and adaptive immune responses in periodontal diseases. *Periodontology* 2000. 2016;71(1):22-51.
95. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;12(01)*.
96. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
97. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
98. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
99. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
100. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
101. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

102. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
103. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
104. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
105. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
106. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
107. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
108. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
109. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;12(01)*.
110. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
111. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
112. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
113. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
114. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
115. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
116. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54

117. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.
118. Obeagu EI. Aplastic Anemia and HIV: Clinical Features and Risk Factors. *Elite Journal of Haematology*, 2024; 2(5): 20-38

**Citation:** Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54